Pharmacological treatment for kleine-levin syndrome

Página do item simplificado
dc.contributor.authorde Oliveira, Marcio M. [UNIFESP]
dc.contributor.authorConti, Cristiane [UNIFESP]
dc.contributor.authorPrado, Gilmar F. [UNIFESP]
dc.date.accessioned2019-01-21T10:29:56Z
dc.date.available2019-01-21T10:29:56Z
dc.date.issued2016
dc.description.abstractBackground This is an updated version of the original Cochrane review, published in 2009, Issue 2. Kleine-Levin syndrome (KLS) is a rare disorder that mainly affects adolescent men. It is characterised by recurrent episodes of hypersomnia, usually accompanied by hyperphagia, cognitive and mood disturbances, abnormal behaviour, such as hypersexuality, and signs of dysautonomia. In 1990, the diagnostic criteria for Kleine-Levin syndrome were modified in the International Classification of Sleep Disorders, where KLS was defined as a syndrome comprised of recurring episodes of undue sleepiness lasting some days, which may or may not be associated with hyperphagia and abnormal behaviour. According to the International Classification of Sleepiness Disorders, 3rd version (ICSD-3), revised in 2014, the Kleine-Levin syndrome is a disorder characterized by recurrent episodes of hypersomnia that last from two days to four weeks, with at least annual recurrence, and hyperphagia (rapid consumption of a large amount of food), usually with onset in early adolescence in males but occasionally in later life and in women. A monosymptomatic form of the disorder with hypersomnia only can occur without binge eating or hypersexuality. The cause of Kleine-Levin syndrome remains unknown, and several treatment strategies have been used. Some medications have been reported to provide benefit in the treatment of patients with KLS, but because of the rarity of the condition, no long-term follow-up therapies have yet been described. Objectives This review aimed to evaluate: 1. whether pharmacological treatment for Kleine Levin syndrome was effective and safe. 2. which drug or category of drugs was effective and safe. Search methods For the latest update, we searched the following sources: the Cochrane Epilepsy Group Specialized Register (7 April 2016)en
dc.description.abstractthe Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online CRSO (7 April 2016)en
dc.description.abstractMEDLINE (1946 to April 2016)en
dc.description.abstractLILACS (7 April 2016)en
dc.description.abstractClinicalTrials.gov (7 April 2016)en
dc.description.abstractWHO International Clinical Trials Registry Platform ICTRP (7 April 2016)en
dc.description.abstractreference lists of sleep medicine textbooksen
dc.description.abstractreview articles and reference lists of articles identified by the search strategies. Selection criteria All randomised controlled trials (RCTs) and quasi-randomised controlled trials looking at pharmacological interventions for Kleine-Levin syndrome were eligible. We had planned to include both parallel-group and cross-over studies. Data collection and analysis Two review authors (MMO and CC) had planned to extract the data reported in the original articles. Main results No studies met the inclusion criteria for this systematic review. Authors' conclusions Therapeutic trials of pharmacological treatment for Kleine-Levin syndrome with a double-blind, placebo-controlled design are needed.en
dc.description.affiliationUniversidade Federal de São Paulo, Rua Pedro de Toledo 598, BR-04039001, São Paulo, Brazil
dc.description.affiliationDepartment of Neurology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Rua Pedro de Toledo 598, BR-04039001, São Paulo, Brazil
dc.description.affiliationUnifespDepartment of Neurology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipNational Institute for Health Research (NIHR), UK, UK
dc.description.sponsorshipNational Institute for Health Research, via Cochrane Infrastructure funding
dc.format.extentCD006685
dc.identifierhttp://dx.doi.org/10.1002/14651858.CD006685.pub4
dc.identifier.citationCochrane Database Of Systematic Reviews. Hoboken, n. 5, p. CD006685, 2016.
dc.identifier.doi10.1002/14651858.CD006685.pub4
dc.identifier.fileWOS000377961800041.pdf
dc.identifier.issn1469-493X
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/49489
dc.identifier.wosWOS:000377961800041
dc.language.isoeng
dc.publisherWiley-blackwell
dc.relation.ispartofCochrane Database Of Systematic Reviews
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectKleine-Levin Syndrome [drug Therapy]en
dc.subjectRare Diseases [drug Therapy]en
dc.subjectHumansLithiumen
dc.subjectCarbamazepineen
dc.subjectEncephalitisen
dc.subjectTherapyen
dc.subjectVarianten
dc.subjectSleepen
dc.subjectAciden
dc.titlePharmacological treatment for kleine-levin syndromeen
dc.typeinfo:eu-repo/semantics/review
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
WOS000377961800041.pdf
Tamanho:
195.12 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Coleções
EPM - Artigos